Lung Cancer/Thoracic Malignancies
AMA PRA Category 1 Credits 1.25
CAMPEP Credits: 1.25
MDCB Credits: 1.25
Alexander Louie, MD, PhD, MSc, FRCPC
Sunnybrook Health Sciences Centre
Toronto, ON, Canada
Stage III NSCLC represents one of the most heterogenous subgroups of lung cancer, wherein there are several multimodality treatment options. These are most often informed in the context of operability and resectability. In the present molecular era, biomarkers also have strong implications in the choice of systemic therapy, as well as prognosis. In practice, the choice and sequence of multimodality treatment varies substantially among clinicians, across institutions, and even within an institution. This multidisciplinary education session, led by representatives from thoracic surgery, radiation oncology and medical oncology will review the current state of the art evaluation, workup and treatment options in stage III NSCLC. Particular emphasis will be placed on the emergence of neoadjuvant immunotherapy-based treatment prior to surgery, and its implication on the role of radiotherapy in the neoadjuvant, definitive and adjuvant scenarios. Finally, practical considerations for future directions and current controversies will be reviewed and discussed.
Speaker: Alexander Louie, MD, PhD, MSc, FRCPC – Sunnybrook Health Sciences Centre
Speaker: Stephen Liu, MD – Georgetown University
Speaker: Erin Gillaspie, MD – Creighton University Medical Center
Speaker: Houda Bahig, MD, PhD – Centre Hospitalier de l'Universite de Montreal (CHUM)
Speaker: Alexander Louie, MD, PhD, MSc, FRCPC – Sunnybrook Health Sciences Centre
Speaker: Alexander Louie, MD, PhD, MSc, FRCPC – Sunnybrook Health Sciences Centre